Today we interview Dr. Bita Fakhri of UCSF on the current research behind treatments for lymphoma. We touch on CAR-T, ABVD, DA-EPOCH-R, and more. We also talk about histiocytic disorders, Dr. Fakhri's career in academia, and learning through teaching.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.16 Treating Lymphoma, Histiocytic Disorders, Learning by Teaching, & More! with Dr. Bita Fakhri

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

4.16 Treating Lymphoma, Histiocytic Disorders, Learning by Teaching, & More! with Dr. Bita Fakhri

Download our free app to listen on your phone